5-(N,N-dimethyl)-Amiloride Hydrochloride: Precision NHE1 Inhibition for Cardiovascular and Endothelial Research

Principle Overview: Targeting the Na+/H+ Exchanger in Disease Models

5-(N,N-dimethyl)-Amiloride hydrochloride (DMA), available from APExBIO, is a potent and selective Na+/H+ exchanger inhibitor. This crystalline amiloride derivative exhibits submicromolar affinity for NHE1 (Ki = 0.02 µM), and substantial selectivity for NHE2 (Ki = 0.25 µM) and NHE3 (Ki = 14 µM), with minimal off-target activity on NHE4, NHE5, and NHE7. The Na+/H+ exchanger (NHE) family is pivotal for intracellular pH regulation, sodium ion transport, and cell volume homeostasis, especially in cardiovascular and endothelial tissues.
Blocking NHE1-driven proton extrusion and sodium influx with DMA directly impacts processes such as tissue acid-base balance, cardiac contractility, and endothelial permeability. This precision is particularly valuable in models of ischemia-reperfusion injury and endothelial dysfunction, where dysregulated sodium and proton transport underpin pathophysiological cascades.

Step-by-Step Workflow: Applied Protocol Enhancements for Reliable NHE Inhibition

1. Reagent Preparation and Handling

• Solubility: DMA dissolves up to 30 mg/ml in DMSO or dimethylformamide. Prepare fresh aliquots to ensure activity, as long-term storage of solutions is not recommended. Solid should be stored at -20°C.
• Stock Solution: For most cell culture and tissue models, a 10 mM stock in DMSO is typical. Dilute into prewarmed buffer or medium immediately before use, keeping final DMSO concentration ≤0.1% to minimize vehicle effects.

2. Cell and Tissue Model Applications

• Cardiac Ischemia-Reperfusion Models: Pre-incubate isolated cardiomyocytes or cardiac tissue slices with 5-(N,N-dimethyl)-Amiloride hydrochloride (0.1–1 μM) for 10–30 minutes before hypoxia/reoxygenation cycles. This pre-treatment has been shown to normalize tissue sodium levels and reduce contractile dysfunction, as reported in both preclinical rodent and ex vivo heart models.
• Endothelial Permeability Assays: In human microvascular endothelial cells (HMECs), pre-treat monolayers with DMA (0.05–0.5 μM) prior to inflammatory stimulation (e.g., LPS, TNF-α) to dissect the contribution of NHE1 to barrier disruption and intracellular pH regulation. Quantify permeability changes using FITC-dextran flux or transendothelial electrical resistance (TEER).
• Metabolic and Ion Transport Studies: Use DMA to probe sodium-dependent uptake (e.g., alanine transport in hepatocytes) and ouabain-sensitive ATPase activity in isolated plasma membranes, leveraging its broader effects on sodium-potassium ATPase inhibition.

3. Endpoint Analyses

• Intracellular pH Measurement: Employ pH-sensitive fluorescent dyes (e.g., BCECF-AM) to monitor rapid changes in response to NHE inhibition.
• Cell Viability and Injury Markers: Assess lactate dehydrogenase (LDH) release, mitochondrial membrane potential, or caspase activation in injury models.
• Sodium Content: Quantify intracellular sodium using flame photometry or sodium-sensitive fluorescent probes to confirm functional inhibition.

Advanced Applications and Comparative Advantages

DMA’s unparalleled specificity for NHE1 makes it the benchmark tool for dissecting Na+/H+ exchanger signaling pathways in cardiovascular disease research. Compared to first-generation amiloride analogs, DMA’s higher affinity and selectivity reduce off-target effects, enabling clearer attribution of observed phenotypes to NHE1 inhibition.
In recent studies on sepsis-induced endothelial injury, intracellular pH regulation and sodium transport emerged as critical factors in the pathogenesis of vascular leak and inflammation. Moesin (MSN), a membrane-cytoskeleton linker, was identified as a biomarker of endothelial damage, with NHE1-mediated pH imbalance implicated in MSN activation and cytoskeletal remodeling. By selectively inhibiting NHE1, DMA offers a direct approach to modulate these injury pathways and study the interplay between ion transport, cytoskeletal dynamics, and inflammatory signaling (see the reference backbone for further context).

For researchers seeking to position their work at the leading edge of translational cardiovascular and endothelial research, DMA (C3505, APExBIO) provides:

• Data-Driven Performance: Submicromolar inhibition enables dose-response studies with high signal-to-noise ratios, critical for quantitative modeling of Na+/H+ exchanger function.
• Workflow Consistency: Batch-tested purity and solubility support reproducible outcomes across single-cell, tissue, and in vivo systems.
• Translational Relevance: Directly informs therapeutic strategies targeting sodium and pH regulation in ischemia-reperfusion injury, sepsis, and heart failure.

For a deeper dive into novel endothelial and cardiac injury models that leverage DMA, see the article "5-(N,N-dimethyl)-Amiloride Hydrochloride: Unveiling Novel...", which extends the application space with biomarker-driven approaches. To compare protocol-specific enhancements and workflow troubleshooting, consult "5-(N,N-dimethyl)-Amiloride (hydrochloride): A Benchmark N..." for validated strategies in translational cardiovascular studies. The article "5-(N,N-dimethyl)-Amiloride Hydrochloride: Empowering NHE1..." complements this discussion by detailing DMA’s precision in dissecting disease mechanisms beyond conventional NHE1 inhibition.

Troubleshooting and Optimization Tips

• Solution Stability: Always prepare DMA solutions fresh from solid stock. Prolonged storage, even at -20°C, may result in hydrolysis or reduced potency. Discard unused DMSO stocks after 1-2 weeks.
• Vehicle Effects: Keep final DMSO/DMF concentrations below 0.1% in cell culture to avoid cytotoxicity. Include vehicle-only controls in all experiments.
• Concentration Range: Start with published Ki values for target isoforms. For NHE1-driven responses, 0.01–0.2 μM is typically sufficient; higher concentrations may be needed for NHE2/NHE3 or in tissue models with diffusion barriers.
• Assay Interference: DMA can inhibit sodium-potassium ATPase at higher concentrations. Confirm specificity by including non-inhibitory analogs (e.g., NHE4-insensitive controls) or using isoform-selective knockdown.
• Endpoint Validation: Use orthogonal readouts (e.g., sodium flux, pH, and functional assays) to confirm NHE inhibition and rule out off-target effects.
• Batch-to-Batch Consistency: Source DMA from a trusted supplier like APExBIO to ensure reproducibility and minimize lot-to-lot variation.

Future Outlook: Expanding the Frontiers of Sodium Transport and Endothelial Research

With the increasing recognition of Na+/H+ exchanger signaling in cardiovascular and inflammatory diseases, 5-(N,N-dimethyl)-Amiloride hydrochloride is poised to support a new generation of mechanistic and translational studies. Emerging areas include:

• Personalized Medicine: Stratifying patient-derived models for NHE1 sensitivity to design tailored cardioprotective interventions.
• Multi-Omics Integration: Combining DMA-mediated NHE inhibition with transcriptomic and proteomic profiling to map downstream effectors in cardiac and endothelial injury.
• Drug Discovery Platforms: Leveraging DMA in high-throughput screens for compounds that synergize with, or modulate, NHE1 activity in disease-relevant contexts.
• Biomarker Validation: Using DMA to validate new markers of endothelial dysfunction—such as moesin (MSN) as highlighted in the study by Chen et al.—and link them to ion transport mechanisms.

In summary, 5-(N,N-dimethyl)-Amiloride (hydrochloride) delivers unmatched precision for dissecting Na+/H+ exchanger signaling pathways and advancing cardiovascular disease research. Its robust workflow compatibility, data-driven reproducibility, and proven performance across cell and tissue models make it an essential reagent for investigators probing the frontiers of intracellular pH regulation, ischemia-reperfusion injury protection, and endothelial dysfunction. APExBIO’s commitment to quality ensures that every experiment is a step closer to translational impact.